Pelubiprofen SR is under clinical development by Daewon Pharmaceutical and currently in Phase III for Chronic Low Back Pain (CLBP). According to GlobalData, Phase III drugs for Chronic Low Back Pain (CLBP) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pelubiprofen SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pelubiprofen SR overview

Pelubiprofen is under development for the treatment of chronic back pain, osteoarthritis, rheumatoid arthritis and low back pain. The drug candidate is administered through oral route. The drug is developing as sustained release formulation. The drug candidate acts by targeting cyclooxygenase 1 and cyclooxygenase 2.

It was also under development for post-traumatic pain.

Daewon Pharmaceutical overview

Daewon Pharm Co Ltd (Daewon) is a pharmaceutical company. It manufactures and supplies pharmaceutical and medicinal products. The company offers Analgesic, Respiratory, Antimicrobial, Cardiovascular, Antidiabetic, Hepatic, Psychoneurotic, Prostate, Multivitamin, Endocrine, Over the counter (OTC) and functional Food. It also sells medical devices such as hearing aids, selling medical devices. The company markets its products in China, Vietnam, Taiwan, Singapore, Hong Kong, Japan, Mongolia, Malaysia, Cambodia, Myanmar, South Korea, the Philippines and Indonesia. Daewon is headquartered in Seoul, South Korea.

For a complete picture of Pelubiprofen SR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.